Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$166.92M+76.16%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joseph Martin Harvey
- Sector
- Financial Services
- Industry
- Asset Management
- Employees
- 424
- Beta
- 1.20
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 12.40
Financials
Revenue
$166.92M+76.2%Net Income
$49.34M+106.7%EBITDA
$74.62M+88.5%Free Cash Flow
$66.37M+137.5%EPS (diluted)
$0.95+86.3%Shares Outstanding (diluted)
51.86M+11.4%Operating Expenses
$0.00Cash & Debt
$612.20MReturn of Capital
$34.92MRevenue by Segment (annual)
$556.12MDividend per Share
$0.67Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $567.80M | $153.22M | $2.99 |
| 2024 | $517.42M | $151.26M | $3.00 |
| 2023 | $489.64M | $129.05M | $2.62 |
| 2022 | $573.72M | $171.04M | $3.51 |
| 2021 | $583.83M | $211.40M | $4.38 |
| 2020 | $430.90M | $76.58M | $1.60 |
| 2019 | $410.83M | $134.62M | $2.85 |
| 2018 | $391.54M | $113.90M | $2.43 |
| 2017 | $383.03M | $91.94M | $1.98 |
| 2016 | $353.62M | $92.94M | $2.02 |
| 2015 | $330.25M | $64.55M | $1.42 |
| 2014 | $313.93M | $75.51M | $1.69 |
| 2013 | $299.99M | $68.12M | $1.54 |
| 2012 | $276.08M | $66.12M | $1.51 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CNS's reported EPS growth of 5.4% a year over 13 years.
- EPS in 5 years
- $3.89
- Implied price
- $81.68
- Return from $73.00
- 2.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $40.61 — -44.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 15 | 18 | 21 | 24 | 27 |
|---|---|---|---|---|---|
| -4.6% | -13.5% | -10.2% | -7.4% | -4.9% | -2.7% |
| 0.4% | -8.9% | -5.5% | -2.6% | 0.1% | 2.4% |
| 5.4% | -4.4% | -0.8% | 2.3% | 5.0% | 7.5% |
| 10.4% | 0.2% | 3.9% | 7.1% | 10.0% | 12.6% |
| 15.4% | 4.7% | 8.6% | 12.0% | 15.0% | 17.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
40-20.00%Social Signal Score
Mentions (17)
- Newsseekingalpha.com·7d ago·Negative
Cohen & Steers: Downgrade To Hold As Higher Interest Rates Cap Share Price Growth Cohen & Steers is downgraded from Buy to Hold due to limited catalysts in a high interest rate environment and premium valuation. Nearly half of CNS' AUM is in US real estate, making the stock sensitive to rising rates and recent fund underperformance. Despite strong net inflows, robust cash flow, and a 3.6% yield, CNS trades at a 90% forward P/E premium to the financial sector median.
View source ↗ - Newsprnewswire.com·13d ago·Negative
Cohen & Steers Closed-End Funds Declare Distributions for October, November, and December 2026 NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for October, November, and December 2026, as summarized in the charts below: Ticker Fund Name Monthly Dividend FOF Cohen & Steers Closed-End Opportunity Fund, Inc. $0.087 LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc. $0.131 PSF Cohen & St
View source ↗ - Newsglobenewswire.com·26d ago·Positive
Pasqal and LG CNS partner to power Next-generation AI Data centers with quantum computing On the sidelines of the France-Korea State Visit, Pasqal strengthens its long-term presence in South Korea by signing a three-year MoU with LG CNS to develop scalable hybrid AI and quantum computing platforms. On the sidelines of the France-Korea State Visit, Pasqal strengthens its long-term presence in South Korea by signing a three-year MoU with LG CNS to develop scalable hybrid AI and quantum computing p…
View source ↗ - Newsprnewswire.com·26d ago·Neutral
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for August 2026 NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $101.0 billion at August 31, 2026, a decrease of $1.5 billion from assets under management of $102.5 billion at July 31, 2026.
View source ↗ - Newsproactiveinvestors.co.uk·34d ago·Negative
Corero spikes 10% on $3.9 million UK telecom and NeoCloud deals Shares in Corero Network Security PLC (AIM:CNS, OTCQB:DDOSF) rose 10% to 8p after itech vendor secured a combined $3.9 million in new agreements to deploy its sovereign cybersecurity defences across the UK telecommunications sector and the global NeoCloud sector. At the heart of the operational update is a pivotal five-year contract worth $3.4 million with a leading UK-based tier 1 fixed and mobile telecommunications provider.
View source ↗ - Newsaccessnewswire.com·34d ago·Positive
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" Segment Access the segment here HOUSTON, TX / ACCESS Newswire / September 1, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtua…
View source ↗ - Newsprnewswire.com·35d ago·Negative
Cohen & Steers and Trademark Acquire Oak Hill Plaza Shopping Center in Austin, Texas NEW YORK, Aug. 31, 2026 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that the Cohen & Steers Real Estate Opportunities Fund (REOF) has acquired Oak Hill Plaza, a shopping center in Austin, Texas. The acquisition was made through a joint venture with Trademark Property Company, a real estate investor, developer, and operator with expertise in retail assets in Texas.
View source ↗ - Newsaccessnewswire.com·39d ago·Neutral
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference Video webcast now available here HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. Rami Levin, President and Chief Executive Offic…
View source ↗ - News (RSS)coindesk·41d ago·Neutral
South Korea trade giant POSCO brings trade receivables to Avalanche in latest tokenization move The $22 billion trading company worked with Olea and Intain on the transaction, following an Injective pilot with LG CNS last month.
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.
View source ↗ - Newsprnewswire.com·47d ago·Negative
…artWall ONE™ Combining Cloud-Scale AI Analysis With Human Expertise for Enhanced Threat Responses LONDON, Aug. 20, 2026 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service ("DDoS") protection specialists and champion of adaptive, real-time service availability, today announced AI-Augmented Cloud-Assist for SmartWall ONE™, extending its automated DDoS protection with cloud-delivered AI analysis, threat intelligence, and policy optimization. As cybe…
View source ↗ - News (RSS)businessinsider·48d ago·Negative
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center"><em>Former Intra-Cellular Therapies, Inc. ("Intra-Cellular") executives bring complementary experience in organizational scale-up, central nervous system ("CNS") drug development, regulatory approvals and commercialization</em><p...
View source ↗ - Newsprnewswire.com·49d ago·Negative
Cohen & Steers and DLC Acquire Royal Plaza Grocery Shopping Center in Front Royal, Virginia NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that the Cohen & Steers Real Estate Opportunities Fund (REOF) has acquired Royal Plaza, a grocery-anchored center in Front Royal, Va., part of the Washington D.C.
View source ↗ - Newsprnewswire.com·52d ago·Neutral
Cohen & Steers Announces Changes to Realty Indexes NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as of the close of business on August 21, 2026. Cohen & Steers Realty Majors Portfolio Index (RMP) Added component (symbol) Removed component (symbol) CareTrust REIT Inc. (CTRE) Cohen & Steers Global Realty Majors Portfolio Index…
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Cohen & Steers Launches Real Assets Active ETF (CSRA) NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced it has launched the Cohen & Steers Real Assets Active ETF (CSRA). This ETF harnesses the firm's four decades of leadership in listed real assets to offer an actively managed, diversified solution investing across real estate, infrastructure, natural resources and commodities.
View source ↗ - Newsaccessnewswire.com·55d ago·Neutral
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focu
View source ↗ - Newsprnewswire.com·56d ago·Neutral
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for July 2026 NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $102.5 billion at July 31, 2026, an increase of $2.4 billion from assets under management of $100.1 billion at June 30, 2026. The increase was due to market appreciation of $1.9 billion and net inflows of $688 million, partially offset by distributions of $155 million.
View source ↗
Earnings
Thu, Oct 15(in 9 days)
Consensus estimate $0.93 per share
Typical surprise -0.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 16$0.85 vs $0.85miss
- Thu, Apr 16$0.79 vs $0.81miss
- Thu, Jan 22$0.81 vs $0.81beat
- Thu, Oct 16$0.81 vs $0.78beat
- Thu, Jul 17$0.73 vs $0.75miss
- Wed, Apr 16$0.75 vs $0.72beat
Estimates and results for CNS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CNS officers and directors.
- Bought
- $2.3m
- Sold
- $2.5m
3 trades
6 trades
- Dulik Elenasold
- Noonan Danielsold
- Cheigh Jonsold
- Poli Francis Csold
- Poli Francis Csold
- Poli Francis Csold
- Cohen Martinbought
- Steers Robert Hamiltonbought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 18, 2025 (19d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 3, 2024 (8d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2020 (32d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 10, 2020 (29d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.